S. Winski

发表

Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes

H. Kantarjian, G. Garcia-Manero, E. Jabbour, 2011 .

Arsenate toxicity in human erythrocytes: characterization of morphologic changes and determination of the mechanism of damage.

D. E. Carter, S. Winski, Carter De, 1998, Journal of toxicology and environmental health. Part A.

Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1.

D. Ross, D. Siegel, S. Winski, 1999, Pharmacogenetics.

A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

H. Kantarjian, G. Garcia-Manero, E. Jabbour, 2014, Clinical Cancer Research.

NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms.

D. Ross, A. Anwar, D. Siegel, 2000, Chemico-biological interactions.

Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice

Deborah H Anderson, K. Koch, J. Winkler, 2012 .

Differential involvement of caspases in hydroquinone-induced apoptosis in human leukemic hl-60 and jurkat cells.

D. Ross, S. Inayat-Hussain, S. Winski, 2001, Toxicology and applied pharmacology.

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Ella T. Lifset, J. Fernandez-Banet, A. Pavlícek, 2022, Nature Medicine.

Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1.

D. Ross, A. Anwar, D. Siegel, 2001, Molecular pharmacology.

NAD(P)H:quinone Oxidoreductase 1 (NQO1): Chemoprotection, Bioactivation, Gene Regulation and Genetic Polymorphisms

D. Ross, A. Anwar, D. Siegel, 2010 .

Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches.

L. Amzel, D. Ross, D. Siegel, 2001, Biochemistry.

Sequence of toxic events in arsine-induced hemolysis in vitro : Implications for the mechanism of toxicity in human erythrocytes

D. E. Carter, D. Barber, S. Winski, 1997 .

Sequence of toxic events in arsine-induced hemolysis in vitro: implications for the mechanism of toxicity in human erythrocytes.

D. E. Carter, D. Barber, S. Winski, 1997, Fundamental and applied toxicology : official journal of the Society of Toxicology.

Indolequinone antitumor agents: relationship between quinone structure and rate of metabolism by recombinant human NQO1.

D. Ross, D. Siegel, C. Moody, 1998, Bioorganic & medicinal chemistry letters.

3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.

N. Gibson, D. Emerson, A. Castelhano, 2006, Bioorganic & medicinal chemistry letters.

Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).

N. Gibson, D. Emerson, A. Castelhano, 2005, Bioorganic & medicinal chemistry letters.

Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.

D. Ross, D. Siegel, C. Moody, 1998, Journal of medicinal chemistry.

Structure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones.

L. Amzel, D. Ross, M. Bianchet, 2001, Structure.

Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release.

L. Amzel, D. Ross, P. Talalay, 2000, Proceedings of the National Academy of Sciences of the United States of America.

A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.

D. Ross, J. Butler, S. Winski, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Interactions of rat red blood cell sulfhydryls with arsenate and arsenite.

D. E. Carter, S. Winski, 1995, Journal of toxicology and environmental health.

Arsenic Metabolism After Pulmonary Exposure

D. E. Carter, M. Peraza, D. Barber, 1999 .

Metabolism and toxicity of sodium arsenate in human erythrocytes

S. Winski, 1997 .

OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models.

G. Wynne, N. Gibson, D. Emerson, 2006, Cancer research.

Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.

D. Ross, D. Dehn, C. Moody, 2001, Biochemical pharmacology.

Selective RET kinase inhibition for patients with RET-altered cancers

A. Drilon, B. Tuch, V. Velcheti, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.

B. Taylor, M. Berger, A. Drilon, 2017, Cancer discovery.

Development of a New Isogenic Cell-Xenograft System for Evaluation of NAD(P)H:Quinone Oxidoreductase-Directed Antitumor Quinones

D. Ross, D. Dehn, S. Winski, 2004, Clinical Cancer Research.

Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells.

Yiannis Koutalos, David Ross, Y. Koutalos, 2002, Cancer research.

Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

K. Pradhan, S. Gross, A. Verma, 2016, Cancer research.

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

Lauren E. Stopfer, Bryan D. Bryson, F. White, 2022, bioRxiv.

162 MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations

B. Tunquist, J. Garrus, R. Woessner, 2010 .

Preclinical Data with KIT D816V Inhibitor Bezuclastinib (CGT9486) Demonstrates High Selectivity and Minimal Brain Penetrance

S. Winski, J. Sachs, K. Bouhana, 2021, Blood.

Main Manuscript for MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas Short title: MEK inhibition reveals targetable MHC-I antigens

Lauren E. Stopfer, Bryan D. Bryson, F. White, 2022 .

Effects of parenteral cysteine and glutathione feeding in a baboon model of severe prematurity.

C. White, R. Allen, S. Stabler, 2000, The American journal of clinical nutrition.

Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor

S. Gross, J. Lyssikatos, K. Koch, 2010 .

Abstract 2514: ARRY-162, A Potent and Selective MEK 1/2 Inhibitor, Shows Enhanced Efficacy in Combination with Other Targeted Kinase Inhibitors and with Chemotherapy

R. Woessner, J. Winkler, Deborah H. Anderson, 2010 .

Effect of arsenic exposure on alveolar macrophage function. II. Effect of slightly soluble forms of As(III) and As(V).

D. E. Carter, R. Lantz, G. Chen, 1995, Environmental research.